Ildiko Csiki
Chief Medical Officer Geneos Therapeutics
Dr Csiki is an oncologist with over 20 years of experience in patient care and cancer research. She currently serves as Chief Medical Officer of Geneos Therapeutics and is a board member of several cancer organizations. Previously, she spent 3 years at the City of Hope Comprehensive Cancer Center as Chief Commercial R&D Officer partnering with City of Hope’s approx. 1000 investigators to accelerate drug discovery, development, and commercialization. Prior to that she served as the Chief Medical Officer at Sensei Bio and completed an executive management program at the Wharton Business School focused on healthcare innovation and entrepreneurship. Prior to Sensei, she held progressively senior roles in industry such as VP of IO at Inovio and Clinical Development Lead for pembrolizumab, GI malignancies at Merck. Dr. Csiki received her M.D. and Ph.D. in Cancer Biology from Vanderbilt University. After residency and a subsequent Holman Pathway Research Fellowship also at Vanderbilt, she began her academic faculty career at the University of Pennsylvania as an Assistant Professor in the Perelman Cancer Center where she had an active clinical practice and a translational science laboratory focused on thoracic malignancies.
Seminars
- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?
